CVC (CVC NA) is said to explore divestments for Recordati (REC IM) after takeover, Bloomberg reports; could consider a sale of Recordati’s rare-diseases arm as one of the alternatives

CVC's exploration of divestments for Recordati following their takeover indicates a strategic shift that could enhance liquidity or refocus on core operations. The potential sale of Recordati’s rare-diseases division points to a prioritization of profitability and may influence investor sentiment regarding the overall value and direction of Recordati's portfolio. Watch for reactions from the market, especially within the healthcare sector, as peers may follow suit in evaluating their own non-core assets.